Start here if you're new
what it is
Maravai sells the ingredients and services drugmakers use to build therapies, diagnostics, and vaccines.
how it gets paid
Last year Maravai made $186M in revenue. North America was the main engine at $91.1M, or 49% of sales.
why growth slowed
Revenue fell 28.3% last year. Gross margin at 15.6% matters most because margin → what you keep after making the product → so what: this rebound still does not look.
what just happened
Revenue jumped to $136M, but EPS was still a loss at -$0.66.
At a glance
B balance sheet — gets the job done, barely
20/100 earnings predictability — expect surprises
6.5% return on capital — nothing to write home about
-$0.10 fy2027 eps est
$300M fy2029 rev est
xvary composite: 38/100 — weak
What they do
Maravai sells the ingredients and services drugmakers use to build therapies, diagnostics, and vaccines.
This company sits in the picks-and-shovels part of biotech. You are not betting on one drug. You are betting that researchers keep buying the hard-to-replace inputs behind mRNA and biologics work. TriLink made up 64% of 2025 revenue mix, which means one core platform still carries the story.
How they make money
$186M
annual revenue · their business grew -28.3% last year
North America
$91.1M
Asia Pacific
$63.2M
EMEA
$31.6M
Other
$0.0M
The products that matter
manufacturing inputs for therapies and vaccines
nucleic acid production
part of $186M revenue
this is the kind of business that ties Maravai to research, diagnostics, and vaccine workflows, but this page does not break out how much of the $186M total it contributes.
core exposure
quality and contamination testing
biologics safety testing
recovery lever
if customer activity comes back, testing demand usually comes with it. The issue is that this page gives you no segment revenue split, so you cannot see which business is carrying the rebound.
watch demand
research tools and detection workflows
protein detection
thin disclosure
the investment question is not whether these tools exist. It's whether they can help move revenue from $186M toward the $300M fy2029 estimate without another margin reset.
prove-it segment
Key numbers
$4
18-month target
That target is only about 8% above the $3.70 stock price. So what: even the optimistic near-term case is pretty small.
-115.9%
operating margin
Operating margin → profit after running the business → so what: Maravai is still losing money badly at the operating level.
$186M
annual revenue
That is down 28.3% vs. prior year. So what: the company is still shrinking after the COVID revenue hangover.
$287M
long-term debt
Debt → money owed to lenders → so what: this is a heavy load for a company with negative operating margin and only $186 million in annual revenue.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 4 — safer than 20% of stocks
- price stability 10 / 100
- long-term debt $287M (23% of capital)
- net profit margin 16.7% — keeps 17 cents of every dollar in revenue
- return on equity 10% — $0.10 profit for every $1 investors have put in
B — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in MRVI 3 years ago → it's now worth $2,660.
The index would have given you $14,770.
source: institutional data · total return
What just happened
beat estimates
Revenue jumped to $136M, but EPS was still a loss at -$0.66.
The top-line rebound looks dramatic because the comparison was weak. The real issue is that gross margin was only 15.6%, so more sales did not translate into healthy profits.
$136M
revenue
$0.66
eps
15.6%
gross margin
the number that mattered
Gross margin at 15.6% matters most because margin → what you keep after making the product → so what: this rebound still does not look like a healthy business.
-
maravai lifesciences’ near-term prospects remain muted.
-
the company is scheduled to release full-year 2025 results after this issue was published.
-
however, our outlook has not altered, with expectations of a revenue decline and narrower share deficit than the year prior.
-
maravai will likely face ongoing operational challenges this year and next.however, cost saving initiatives, and streamlining efforts are expected to help top- and bottom-line progress in 2026 and 2027.
-
the newly named ceo intends to pare expenses in an effort to improve business fundamentals.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is that demand does not stabilize after a 28.3% revenue drop. if the recovery stays a slide deck story, the stock will keep trading like one.
high
customer demand in therapies, diagnostics, and vaccines stays soft
Maravai sells into life-science activity levels. If customer budgets, project starts, or manufacturing demand stay weak, another period of shrinking revenue becomes very possible.
direct risk to the $186M base and the recovery path toward $300M
med
margins stay too thin to absorb volatility
The reported gross margin on this page is 15.6%. That does not leave much room for another demand wobble, pricing pressure, or underused capacity.
small revenue misses can turn into outsized earnings disappointment
med
the balance sheet stops being merely adequate
A B balance sheet is fine until the business needs more flexibility. With $287M of long-term debt and a volatile share price, the margin for error is not huge.
more balance-sheet pressure would matter fast in a $950M company
low
the stock stays cheap because the market wants proof, not forecasts
A $4 midpoint on a $3.70 stock tells you sentiment is cautious. Even decent execution may not be enough if investors want several quarters of evidence first.
upside can stay capped even if the business improves slowly
If revenue does not start moving from $186M toward the $300M fy2029 estimate, the recovery case gets thinner and the current valuation framework starts looking generous.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
revenue stabilization
The first question is not growth. It's whether revenue stops falling after the 28.3% decline. If that line keeps moving the wrong way, everything else gets harder.
calendar
next earnings update
Use the next update to check whether management can show actual stabilization, not just a better narrative. Last full review on this page: feb 6, 2026.
risk
debt versus flexibility
Keep one eye on the $287M long-term debt load. In a volatile small cap, an adequate balance sheet can feel less adequate in a hurry.
trend
path to $300M
The fy2029 revenue estimate is $300M. You do not need it to get there tomorrow, but you do need the next few reports to make that path look less theoretical.
Analyst rankings
short-term outlook
balanced
the $4 midpoint sits close to the current stock price. in human-speak, analysts are not modeling a dramatic near-term rerating.
risk profile
volatile
10/100 price stability and a small-cap healthcare label usually mean wider swings than the average stock.
chart momentum
stock-specific
this name is likely to move more on company proof points than on a smooth market trend.
earnings predictability
20/100
that is another way of saying estimates are fragile. when the business changes shape, forecasts usually do too.
source: institutional data
Institutional activity
institutions have been net buying for 2 consecutive quarters — 74 buyers vs. 63 sellers in 3q2025. total institutional holdings: 0.1B shares. net buying for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$1
$6
$4
current price
$4
target midpoint · +8% from current · 3-5yr high: $4 (+10% · 2% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive